Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat Tosylate in Relapse/Refractory B-cell Lymphoma
NCT04842877Phase 2Active, not recruiting
- Sponsor
- LYSARC
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of valemetostat in B-cell non-Hodgkin lymphoma, Hodgkin lymphoma (HL), sponsored by LYSARC. Started Jun 2021; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
B-cell non-Hodgkin lymphomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04842877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842877.